Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Fennec Pharmaceuticals

21/03/2024 13:32

* Fennec Pharmaceuticals Inc  FENC.OQ  reported a quarterly
adjusted loss of 10 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -26 cents.  The mean expectation of
five analysts for the quarter was for a loss of 2 cents per
share. Wall Street expected results to range from -10 cents to 3
cents per share.
    * Revenue rose 534.2% to $9.74 million from a year ago;
analysts
expected $8.67 million. 
    * Fennec Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The company reported a quarterly loss of $2.68 million.
    * Fennec Pharmaceuticals Inc shares had fallen by 1.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 40%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.00 

This summary was machine generated from LSEG data March 21 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.02          -0.10          Missed
 Sep. 30 2023      -0.12          -0.07          Beat
 Jun. 30 2023      -0.16          -0.21          Missed
 Mar. 31 2023      -0.21          -0.23          Missed